Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade D 12.26 -3.08% -0.39
ATNX closed down 3.08 percent on Friday, March 22, 2019, on 1.18 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ATNX trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 21 Crossed Above 20 DMA Bullish -3.08%
Mar 21 MACD Bullish Signal Line Cross Bullish -3.08%
Mar 20 Crossed Above 50 DMA Bullish 0.99%
Mar 20 NR7 Range Contraction 0.99%
Mar 19 20 DMA Resistance Bearish 1.74%
Mar 19 Fell Below 50 DMA Bearish 1.74%
Mar 19 Inside Day Range Contraction 1.74%
Mar 18 20 DMA Resistance Bearish -1.13%

Older signals for ATNX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Chemistry Organic Compounds Oncology Chemotherapy Cancers Organic Chemistry Antineoplastic Drugs Therapies For Cancer Pruritus Docetaxel Paclitaxel Scars Treatment Of Various Types Of Cancers
Is ATNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.9
52 Week Low 9.83
Average Volume 234,286
200-Day Moving Average 14.5845
50-Day Moving Average 12.14
20-Day Moving Average 12.38
10-Day Moving Average 12.022
Average True Range 0.5448
ADX 14.41
+DI 23.6102
-DI 15.4227
Chandelier Exit (Long, 3 ATRs ) 12.1156
Chandelier Exit (Short, 3 ATRs ) 12.8444
Upper Bollinger Band 13.5346
Lower Bollinger Band 11.2254
Percent B (%b) 0.45
BandWidth 18.652666
MACD Line -0.0497
MACD Signal Line -0.0603
MACD Histogram 0.0107
Fundamentals Value
Market Cap 699.6 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -3.53
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.88
Resistance 3 (R3) 12.94 12.81 12.77
Resistance 2 (R2) 12.81 12.65 12.77 12.74
Resistance 1 (R1) 12.53 12.55 12.47 12.47 12.70
Pivot Point 12.40 12.40 12.36 12.36 12.40
Support 1 (S1) 12.12 12.24 12.06 12.06 11.82
Support 2 (S2) 11.99 12.14 11.95 11.78
Support 3 (S3) 11.71 11.99 11.75
Support 4 (S4) 11.65